HROW

Harrow Health Inc

HROW, USA

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

https://www.harrow.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
HROW
stock
HROW

Nothing is Better Than Harrow Inc (HROW) stock at the moment setenews.com

Read more →
HROW
stock
HROW

Eye Drops Maker Sets Up After Strategic Buy; Sales Outlook Strong Investor's Business Daily

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$70.625

Analyst Picks

Strong Buy

4

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

39.22

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

2.17 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

0.28 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

22.86 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

6.73

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 58.75% of the total shares of Harrow Health Inc

1.

Opaleye Management Inc

(10.5534%)

since

2025/06/30

2.

BlackRock Inc

(6.9336%)

since

2025/06/30

3.

Private Capital Management, LLC

(5.2574%)

since

2025/06/30

4.

Vanguard Group Inc

(5.0518%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(2.587%)

since

2025/07/31

6.

BRAIDWELL LP

(2.3573%)

since

2025/06/30

7.

Geode Capital Management, LLC

(2.1912%)

since

2025/06/30

8.

State Street Corp

(2.0894%)

since

2025/06/30

9.

iShares Russell 2000 ETF

(2.0529%)

since

2025/08/31

10.

Citadel Advisors Llc

(1.807%)

since

2025/06/30

11.

Marshall Wace Asset Management Ltd

(1.5266%)

since

2025/06/30

12.

Royce & Associates, LP

(1.4964%)

since

2025/06/30

13.

Rice Hall James & Associates, LLC

(1.0016%)

since

2025/06/30

14.

Morgan Stanley - Brokerage Accounts

(0.9865%)

since

2025/06/30

15.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9205%)

since

2025/07/31

16.

Private Capital Management Value Focus

(0.8771%)

since

2025/03/31

17.

Fidelity Small Cap Index

(0.8543%)

since

2025/06/30

18.

Northern Trust Corp

(0.8502%)

since

2025/06/30

19.

iShares Russell 2000 Growth ETF

(0.7524%)

since

2025/08/31

20.

Charles Schwab Investment Management Inc

(0.6976%)

since

2025/06/30

21.

First Turn Management LLC

(0.6182%)

since

2025/06/30

22.

Stifel Financial Corp

(0.582%)

since

2025/06/30

23.

Susquehanna International Group, LLP

(0.5781%)

since

2025/06/30

24.

Bank of America Corp

(0.5769%)

since

2025/06/30

25.

D. E. Shaw & Co LP

(0.5626%)

since

2025/06/30

26.

Westside Investment Management, Inc.

(0.4893%)

since

2025/06/30

27.

Fidelity Extended Market Index

(0.4618%)

since

2025/07/31

28.

Royce Small-Cap Opportunity Invmt

(0.4146%)

since

2025/06/30

29.

Vanguard Russell 2000 ETF

(0.4065%)

since

2025/07/31

30.

Schwab US Small-Cap ETF™

(0.4037%)

since

2025/08/30

31.

Private Capital Management Value I

(0.3481%)

since

2025/06/30

32.

Royce Micro Cap Trust

(0.3432%)

since

2025/06/30

33.

Private Capital Value Equity

(0.3309%)

since

2025/03/31

34.

FTGF RY US SmCp Opp A USD Dis(A)

(0.3126%)

since

2025/08/31

35.

State St Russell Sm Cap® Indx SL Cl I

(0.2927%)

since

2025/08/31

36.

Vanguard Health Care ETF

(0.263%)

since

2025/07/31

37.

SPDR® S&P Pharmaceuticals ETF

(0.2506%)

since

2025/08/31

38.

iShares US Pharmaceuticals ETF

(0.2294%)

since

2025/08/31

39.

MEDICAL BioHealth EUR Acc

(0.2237%)

since

2025/06/30

40.

Schwab Small Cap Index

(0.2176%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.4625

Latest Release

Date

2025-09-30

EPS Actual

0.33

EPS Estimate

0.24

EPS Difference

0.09

Surprise Percent

37.5%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(6.3)
GARP
Fair GARP(3.5)
Growth
Moderate Growth(4)
Momentum
Moderate Momentum(5.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(4)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.